CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dumont, J. A.
Right arrow Articles by Cross-Doersen, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dumont, J. A.
Right arrow Articles by Cross-Doersen, D. E.

Cell Growth & Differentiation, Vol 7, Issue 3 351-359, Copyright © 1996 by American Association of Cancer Research


ARTICLES

Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity

JA Dumont, AJ Bitonti, CD Wallace, RJ Baumann, EA Cashman and DE Cross-Doersen
Marion Merrell Dow Research Institute, Cincinnati, Ohio 45215, USA.

We have isolated a variant of the MCF-7 human breast tumor that is characterized by a hormone-independent, yet hormone-responsive, phenotype. This tumor, designated MCF-WES, was derived from MCF-7 tumor cells implanted in the mammary fat pad of a nude mouse in the absence of estradiol supplementation. MCF-WES tumors remain responsive to estradiol; however, unlike the parental MCF-7 tumors, they are stimulated to grow by tamoxifen. Additionally, MCF-WES cells are resistant to the pure steroidal antiestrogen, ICI 182,780. To our knowledge, a tumor with this combination of properties has not yet been described. Nuclear estrogen receptor (ER) levels in MCF-WES cells were 10% of those for MCF-7 under steroid-depleted conditions. MCF-WES tumor ER levels were 32% of those in MCF-7 tumors. Similarly, in vivo expression of ER mRNA for MCF-WES was 20% of levels determined for MCF-7. Further characterization of MCF-WES cells showed that they have increased levels of AP-1 DNA-binding activity. The marked increase in AP-1 binding activity may act to bypass the hormone dependence that is a characteristic of MCF-7 cells. It is also probable that the increase in AP-1 binding activity is responsible for the finding that MCF-WES cells secrete greater quantities of metalloproteinase activity in comparison to parental MCF-7 cells, suggesting progression to a more invasive, malignant phenotype. More complete characterization of this new cell line will help elucidate hormone-independent breast cancer and possibly identify targets for therapy.


This article has been cited by other articles:


Home page
Mol Cancer ResHome page
L. Malorni, M. Giuliano, I. Migliaccio, T. Wang, C. J. Creighton, M. Lupien, X. Fu, S. G. Hilsenbeck, N. Healy, C. De Angelis, et al.
Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
Mol. Cancer Res., May 1, 2016; 14(5): 470 - 481.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
M. Oyama, T. Nagashima, T. Suzuki, H. Kozuka-Hata, N. Yumoto, Y. Shiraishi, K. Ikeda, Y. Kuroki, N. Gotoh, T. Ishida, et al.
Integrated Quantitative Analysis of the Phosphoproteome and Transcriptome in Tamoxifen-resistant Breast Cancer
J. Biol. Chem., January 7, 2011; 286(1): 818 - 829.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
Y. Zhang, H. Zhao, S. Asztalos, M. Chisamore, Y. Sitabkhan, and D. A. Tonetti
Estradiol-Induced Regression in T47D:A18/PKC{alpha} Tumors Requires the Estrogen Receptor and Interaction with the Extracellular Matrix
Mol. Cancer Res., April 1, 2009; 7(4): 498 - 510.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
S. AUGUSTIN, M. BERARD, S. KELLAF, N. PEYRI, F. FAUVEL-LAFEVE, C. LEGRAND, L. HE, and M. CREPIN
Matrix Metalloproteinases Are Involved in Both Type I (Apoptosis) and Type II (Autophagy) Cell Death Induced by Sodium Phenylacetate in MDA-MB-231 Breast Tumour Cells
Anticancer Res, April 1, 2009; 29(4): 1335 - 1343.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
S. Safe and K. Kim
Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways
J. Mol. Endocrinol., November 1, 2008; 41(5): 263 - 275.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. B. Riggins, J. P-J. Lan, U. Klimach, A. Zwart, L. R. Cavalli, B. R. Haddad, L. Chen, T. Gong, J. Xuan, S. P. Ethier, et al.
ERR{gamma} Mediates Tamoxifen Resistance in Novel Models of Invasive Lobular Breast Cancer
Cancer Res., November 1, 2008; 68(21): 8908 - 8917.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
A. Ring and M. Dowsett
Mechanisms of tamoxifen resistance
Endocr. Relat. Cancer, December 1, 2004; 11(4): 643 - 658.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Q.-B. She, N. Chen, A. M. Bode, R. A. Flavell, and Z. Dong
Deficiency of c-Jun-NH2-terminal Kinase-1 in Mice Enhances Skin Tumor Development by 12-O-Tetradecanoylphorbol-13-Acetate
Cancer Res., March 1, 2002; 62(5): 1343 - 1348.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. J. Chisamore, Y. Ahmed, D. J. Bentrem, V. C. Jordan, and D. A. Tonetti
Novel Antitumor Effect of Estradiol in Athymic Mice Injected with a T47D Breast Cancer Cell Line Overexpressing Protein Kinase C{alpha}
Clin. Cancer Res., October 1, 2001; 7(10): 3156 - 3165.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar
Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance
Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
L. Adam, R. Vadlamudi, M. Mandal, J. Chernoff, and R. Kumar
Regulation of Microfilament Reorganization and Invasiveness of Breast Cancer Cells by Kinase Dead p21-activated Kinase-1
J. Biol. Chem., April 21, 2000; 275(16): 12041 - 12050.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. H. Talukder, L. Adam, A. Raz, and R. Kumar
Heregulin Regulation of Autocrine Motility Factor Expression in Human Tumor Cells
Cancer Res., January 1, 2000; 60(2): 474 - 480.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
J. Y. Chung, C. Huang, X. Meng, Z. Dong, and C. S. Yang
Inhibition of Activator Protein 1 Activity and Cell Growth by Purified Green Tea and Black Tea Polyphenols in H-ras-transformed Cells: Structure-Activity Relationship and Mechanisms Involved
Cancer Res., September 1, 1999; 59(18): 4610 - 4617.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. R. D. Johnston, B. Lu, G. K. Scott, P. J. Kushner, I. E. Smith, M. Dowsett, and C. C. Benz
Increased Activator Protein-1 DNA Binding and c-Jun NH2-Terminal Kinase Activity in Human Breast Tumors with Acquired Tamoxifen Resistance
Clin. Cancer Res., February 1, 1999; 5(2): 251 - 256.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
P. Bhat-Nakshatri, T. R. Newton, R. Goulet Jr., and H. Nakshatri
NF-{kappa}B activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1{alpha}
PNAS, June 9, 1998; 95(12): 6971 - 6976.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
J. I. Macgregor and V. C. Jordan
Basic Guide to the Mechanisms of Antiestrogen Action
Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1996 by the American Association of Cancer Research.